NEWS
12. July 2010
>RELDATA Named Tech Awards Circle Winner / Unified Block and File Storage Solutions Provider Selected ...
18. June 2010
>RELDATA Selected as AlwaysOn East Top 100 Winner for Cloud and Infrastructure Technology Unified Storage ...
7. June 2010
>On June 24, 2010, the 8th annual Grazia Equity Business Plan Competition was hosted at ...
5. June 2010
>immatics announces Phase II Results with its Therapeutic Cancer Vaccine IMA901 in Patients with Advanced ...
2. June 2010
>Online-Brillenhändler Mister Spex zählt zu "Red Herring 100 Europe" Unternehmen Red Herring Europe Award ...
2. June 2010
>immatics enters Collaboration with the National Cancer Institute (NCI) to Advance the Development of IMA950 ...
16. February 2010
>immatics Enters Collaboration with Cancer Research UK to Develop Multi-target Rationally Designed Therapeutic Cancer Vaccine ...
4. February 2010
>XConnect revenue doubled in 2009 XConnect, the leader in next-generation interconnection and carrier ENUM-registry ...
1. February 2010
>Online-Brillenhändler Mister Spex hat 2009 Brillen und Kontaktlinsen für rund 4,5 Millionen Euro verkauft – ...
26. January 2010
>RELDATA UNIFIED STORAGE NAMED ONE OF “100 COOLEST CLOUD COMPUTING PRODUCTS” BY EVERYTHING CHANNEL’S CRN ...
20. January 2010
>RELDATA (www.reldata.com), a provider of software-centric unified storage solutions, announced today its new RELDATA Partner ...
14. January 2010
>HORIZONT und Statista starten Portal HORIZONTstats.de Premium-Initiative für Paid Content Auf HORIZONTstats.de gibt es ...
9. December 2009
>First Chip Supplier to Offer 4x4 MIMO Wi-Fi Devices Will Play Active Role in One ...
2. December 2009
>Conergy Solar Factory in Frankfurt (Oder): Three Years "Quality Made in Germany" Ramp ...
20. November 2009
>Investoren-Einstieg unterstützt weitere Wachstumsstrategie Der Stuttgarter Finanzinvestor Grazia Equity ist beim After Sales Dienstleister ...
16. November 2009
>Allzu viele Partner bei der Finanzierung können das Wachstum eines jungen Unternehmens stören. Es kommt ...
22. October 2009
>COPRO will sich mit allen Projekten in der virtuellen Welt Twinity präsentieren. Als erstes ...
19. October 2009
>Mit Mister Spex bringt Dirk Graber den Durchblick zurück. Wir haben ihn zu seiner Arbeit ...
5. October 2009
>Statistik-Portal startet heute sein Premium-Angebot, das für 29,90 Euro pro Monat die Verwendung exklusiver Daten ...
1. October 2009
>"Gründerszene ist sehr unterentwickelt" Von Claus G. Schmalholz Lothar Späth, zuletzt Vorsitzender der ...
29. September 2009
>immatics biotechnologies GmbH today announced the appointment of Dr Carsten Reinhardt as Chief Medical Officer ...
22. September 2009
>RELDATA Introduces Next Generation 9240i Unified Storage System Powered by Enhanced RELvos 2.4 Virtualization OS ...
16. September 2009
>Venture capital firms Venrock Associates, Accel Partners, Grazia Equity and Crescent Point Group all participated ...
9. September 2009
>Nanosolar Completes Panel Factory, Commences Serial Production Today Nanosolar demonstrated the completion of its ...
9. September 2009
>Nanosolar Unveils Nanosolar Utility Panel™ Technology In conjunction with today's inauguration of our panel-assembly ...
9. September 2009
>NREL Certifies 16.4% Nanosolar Foil Efficiency It was May 2006 when we last released ...
10. August 2009
>immatics biotechnologies GmbH today announced that the company obtained European patent protection for the composition ...
7. August 2009
>How creativity is helping the German capital cope with economic crisis. BERLIN — The ...
27. July 2009
>Portal will Informationen für Marketingentscheider bündeln Mit einem neuen Seitenkonzept will das Statistik-Portal „Statista“ ...
21. July 2009
>RELDATA Named a CRN Emerging Technology Vendor RELDATA's unified storage solutions provide channel partners ...
7. July 2009
>Ehemaliger Ministerpräsident arbeitet für Venture Capital-Geber: Lothar Späth berät Grazia Equity Prof. Dr. h.c. ...
7. July 2009
>Metaversum GmbH, developer of Twinity, the world’s first mirror world – a virtual world made ...
3. July 2009
>Grazia Equity Award für die beste Geschäftsidee an der HHL Von einer Charityplattform ...
30. June 2009
>Conergy sells solar portfolio with a capacity of 10.7 MWp ...
17. June 2009
>immatics biotechnologies significantly improves XPRESIDENT™ technology platform. immatics biotechnologies today announced the completion of ...
10. June 2009
>Australia: Planning Approval for 282 Wind Turbines EPURON reaches key milestone for the largest ...
8. June 2009
>Conergy Deutschland GmbH sells the Heimpersdorf megawatt solar park to investor Conergy Deutschland GmbH ...
5. June 2009
>Die zweite Auflage des Buches "IT-Governance in der Praxis" von den Autoren Andreas Rüter (Grazia ...
29. May 2009
>moviepilot.de: Führender personalisierbarer Entertainmentguide für Kino, DVD und TV schließt zweite Finanzierungsrunde ab Berlin, 29.05.2009 ...
19. May 2009
>Solarstrom von Conergy reduziert Kosten für Wasserversorgung in Kalifornien • 1,6 MWp Solarpark im ...
14. May 2009
>Statista startet Geschäftskunden-Angebot Statistik-Portal bietet umfassende Markenreports und kostengünstige Online-Umfragen Ausführliche Analysen zu ...
8. May 2009
>Solar energy from the region, for the region: Conergy Deutschland inaugurates a megawatt class thin-film ...
28. April 2009
>XCONNECT NAMES RICHARD SHOCKEY, ENUM PIONEER AND IP COMMUNICATIONS EXPERT, TO ADVISORY BOARD Appointment ...
27. April 2009
>RELDATA EXPANDS ITS SALES ORGANIZATION Industry Veteran Peter Cmaylo joins RELDATA as VP Sales ...
22. April 2009
>XCONNECT EXPANDS GLOBAL ALLIANCE FEDERATION SERVICES Innovations Bring Communications Service Providers More NGN ...
20. April 2009
>Must-have-Accessoires: Hält die Brille mit der It-Bag Schritt? Das Mister Spex "Brillen-Mode-Barometer" analysiert ...
8. April 2009
>Metaversum and Twinity has been elected a Red Herring 100 Europe Winner 2009 With ...
24. March 2009
>OVERGENCE SESSION MANAGER LATEST VOIP-PEERABLE DEVICE CERTIFIED XCONNECT-READY Testing for ENUM Query Compatibility Streamlines ...
2. March 2009
>immatics completes patient recruitment in phase II study with cancer vaccine IMA901 for renal cell ...
24. February 2009
>Quantenna Raises $15 Million in Series D Financing Round Quantenna Communications, Inc., a leader ...
24. February 2009
>RELDATA AND XYRATEX ENABLE HETEROGENEOUS STORAGE RELDATA 9240 and Xyratex F6412E RAID system certification ...
26. January 2009
>immatics wins 29th German Industry’s Innovation Award (Innovationspreis der deutschen Wirtschaft) Tuebingen, January 26, ...
26. January 2009
>The Growing Market for Solar Cells Printing is playing a key role in ...
24. January 2009
>VC Investing Drops For 2008, But Green Grows Venture capital investment shrank in 2008 ...
21. October 2008
>Metaversum Awarded Funding in Co-space™ program in Singapore Metaversum, developer and operator of ...
5. September 2008
>Wowereit Opens Virtual Berlin in Twinity Metaversum GmbH, developer and operator of the ...
16. February 2010
immatics & Cancer Research UK
immatics Enters Collaboration with Cancer Research UK to Develop Multi-target Rationally Designed Therapeutic Cancer Vaccine
IMA950 to enter Phase I development for glioblastoma, the most aggressive form of brain cancer
immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing rationally designed therapeutic vaccines that are active against cancer, today announced it has signed a collaboration with Cancer Research UK for the further development of immatics’ therapeutic cancer vaccine IMA950 in glioblastoma, the most aggressive form of brain cancer. Under the terms of the agreement, Cancer Research UK will sponsor and conduct a Phase I trial of IMA950 to be carried out at leading glioma research centres in the UK via its Drug Development Office. immatics will supply the drug IMA950 for the trial and also undertake immunomonitoring in the treated patients.
After the completion of the study, immatics will have an exclusive first right to take a license to the data for further development of IMA950. No financial details were disclosed.
Paul Higham, CEO of immatics said: “Cancer Research UK is a world-renowned cancer research organisation and we are delighted that through this collaboration we will be able to efficiently move our third therapeutic cancer vaccine into the clinic, highlighting the wide applicability and productivity of our XPRESIDENT™ technology platform.”
Dr Victoria John, head of clinical partnerships at Cancer Research UK’s Drug Development Office, said: “We’re very pleased to be taking on the next stage of this vaccine’s development. This form of glioma is very difficult to treat successfully and we hope this trial will help to establish if the immatics vaccine might offer another viable treatment option for people with this type of cancer.”
IMA950 is a therapeutic cancer vaccine generated through immatics’ proprietary XPRESIDENT™ technology. It consists of 11 tumour-associated peptides (TUMAPs) which the immatics platform selects on the basis of their natural presentation by tumour tissue, immunogenicity and their relevance to tumour function. This unique approach to rationally designed therapeutic vaccines which are a combination of multiple, highly relevant tumour peptides is at the core of all immatics’ clinical programmes.
For additional information on immatics please visit www.immatics.com or contact:
Katrin Eckert, Assistant to the Management
immatics biotechnologies GmbH
Phone: +49-7071-5397-110
E-mail: media@immatics.com
Citigate Dewe Rogerson
David Dible / Chris Gardner / Amber Bielecka
Phone: +44 207 638 9571
E-mail: david.dible@citigatedr.co.uk
About immatics
immatics biotechnologies is a clinical-stage biopharmaceutical company developing rationally designed therapeutic vaccines that are active against cancer. immatics’ lead product, IMA901 has completed a Phase II trial in renal cell carcinoma. immatics’ pipeline also includes IMA910, in Phase II for colorectal cancer, and IMA950 which is being developed for glioma.
immatics’ technology platform rapidly generates defined therapeutic cancer vaccines which are based on multiple tumour-associated peptides (TUMAPs) with the ability to specifically stimulate the immune system against cancer cells. These vaccines – comprising multiple peptides confirmed to be naturally presented by real tumour tissue – offer the prospect of greater effectiveness than existing cancer vaccine approaches. immatics’ products are ‘drug like’ with stable, off-the-shelf formulations and robust easily scalable manufacturing.
immatics is based in Tuebingen and Munich, Germany, and has raised more than €54 million (US$ 72million) in private equity in two financing rounds.
About Cancer Research UK
• Cancer Research UK is the world’s leading charity dedicated to beating cancer through research.
• The charity’s groundbreaking work into the prevention, diagnosis and treatment of cancer has helped save millions of lives. This work is funded entirely by the public.
• Cancer Research UK has been at the heart of the progress that has already seen survival rates double in the last thirty years.
• Cancer Research UK supports research into all aspects of cancer through the work of more than 4,800 scientists, doctors and nurses.
• Together with its partners and supporters, Cancer Research UK's vision is to beat cancer.
For further information about Cancer Research UK's work or to find out how to support the charity, please call 020 7121 6699 or visit www.cancerresearchuk.org